NASDAQ:RXRX • US75629V1044
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RECURSION PHARMACEUTICALS-A (RXRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-26 | Needham | Reiterate | Buy -> Buy |
| 2026-02-26 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-12-17 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-09-11 | Needham | Reiterate | Buy -> Buy |
| 2025-07-08 | Needham | Reiterate | Buy -> Buy |
| 2025-06-16 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-06 | Needham | Maintains | Buy -> Buy |
| 2025-04-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-02-28 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2025-02-06 | Needham | Reiterate | Buy -> Buy |
| 2025-01-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-12-11 | Needham | Reiterate | Buy -> Buy |
| 2024-11-20 | Needham | Reiterate | Buy -> Buy |
| 2024-11-07 | Needham | Reiterate | Buy -> Buy |
| 2024-09-04 | Needham | Maintains | Buy -> Buy |
| 2024-09-03 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2024-09-03 | Jefferies | Maintains | Hold -> Hold |
| 2024-08-09 | Needham | Maintains | Buy -> Buy |
| 2024-07-11 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-06-25 | Needham | Reiterate | Buy -> Buy |
| 2024-05-10 | Needham | Reiterate | Buy -> Buy |
| 2024-04-09 | Needham | Reiterate | Buy -> Buy |
| 2024-03-04 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-28 | Needham | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 44.575M 11.89% | 58.839M 32.00% | 74.681M 26.92% | 83.726M 12.11% | 152.82M 82.52% | 151.42M -0.92% | 252.45M 66.72% | 370.87M 46.91% | 529.69M 42.82% | 774.18M 46.16% | |
| EBITDA YoY % growth | -324.458M -38.68% | -442.51M -36.38% | -564.431M -27.55% | -451.14M 20.07% | -439.114M 2.67% | -412.404M 6.08% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -348.86M -41.97% | -479.004M -37.31% | -648.132M -35.31% | -537.542M 17.06% | -291.613M 45.75% | -84.164M 71.14% | -605.37M -619.28% | -561.612M 7.23% | -503.472M 10.35% | -397.188M 21.11% | |
| Operating Margin | -782.64% | -814.09% | -867.87% | -642.03% | -190.82% | -55.58% | -239.80% | -151.43% | -95.05% | -51.30% | |
| EPS YoY % growth | -1.57 -14.60% | -1.66 -5.73% | -1.48 10.84% | -0.98 33.75% | -0.87 11.44% | -0.95 -9.84% | -0.96 -0.53% | -0.81 15.96% | -0.66 17.72% | -0.48 27.69% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.28 44.04% | -0.27 34.61% | -0.33 7.07% | -0.35 -68.38% |
| Revenue Q2Q % growth | 17.809M 20.78% | 17.806M -7.37% | 21.114M 308.00% | 24.047M -32.33% |
| EBITDA Q2Q % growth | -123.96M 27.95% | -120.33M 9.56% | -145.182M -34.45% | -138.21M -461.08% |
| EBIT Q2Q % growth | -135.293M 29.30% | -132.606M 24.75% | -127.696M 25.84% | -159.256M -47.00% |
All data in USD
14 analysts have analysed RXRX and the average price target is 7.14 USD. This implies a price increase of 119.86% is expected in the next year compared to the current price of 3.2475.
RECURSION PHARMACEUTICALS-A (RXRX) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of RECURSION PHARMACEUTICALS-A (RXRX) is -0.28 USD and the consensus revenue estimate is 17.81M USD.
The expected long term growth rate for RECURSION PHARMACEUTICALS-A (RXRX) is 34.09%.